(IPSC) Century Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IPSC) Century Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Century Therapeutics, Inc. 4P's Marketing Mix Analysis explains the company’s product offering (cellular therapies), its intended clinical/commercial use, pricing considerations, channels, and promotional tactics in a concise, actionable format. This page includes a real preview/sample of the analysis so you can evaluate style and content—purchase the full version to unlock the complete ready-to-use report.
Product
CNTY-101 CD19 CAR-iNK
CNTY-101 is Century Therapeutics, Inc.'s lead clinical program and most advanced asset: an allogeneic iPSC-derived CAR-iNK therapy aimed at CD19 in relapsed or refractory B-cell lymphoma. As the flagship Product in the lineup, it sits at the center of the company’s product strategy and pipeline value. Its market role is clear: a cell therapy designed for hard-to-treat blood cancers where current options often fail.
CNTY-103 CD133+EGFR CAR-iNK
CNTY-103 is Century Therapeutics, Inc.’s allogeneic CAR-iNK candidate for recurrent glioblastoma, aimed at CD133 and EGFR, two markers linked to tumor growth and recurrence. The product pushes Century Therapeutics, Inc. beyond cell therapy for blood cancers into solid tumors, a far larger market where glioblastoma still has a median survival near 15 months and a 5-year survival below 5%. This gives the program clear product differentiation and high unmet-need pull.
CNTY-102 CD19+CD79b CAR-iT
CNTY-102 is Century Therapeutics, Inc.'s CAR-iT candidate in development for relapsed or refractory B-cell lymphoma and other B-cell cancers. It targets both CD19 and CD79b, two validated B-cell antigens, to help address antigen escape. In the 4P mix, this is a high-value Product aimed at patients with strong unmet need in a crowded hematology market.
CNTY-104 AML multi-specific CAR-iT or CAR-iNK
CNTY-104 is Century Therapeutics, Inc.'s multi-specific cell therapy for acute myeloid leukemia, built as either CAR-iT or CAR-iNK. It widens the pipeline into myeloid malignancies, a hard-to-treat area where U.S. AML still causes about 20,800 new cases a year and about 11,220 deaths.
For the 4P lens, the product targets a high-unmet-need niche with a broader antigen strategy than a single-target CAR. That matters because AML has a 5-year relative survival near 32.9%, so even small gains can drive strong clinical and commercial value.
- Target: acute myeloid leukemia
- Format: CAR-iT or CAR-iNK
- Role: expands myeloid pipeline
- Need: high unmet, low survival
CNTY-106 multiple myeloma program
CNTY-106 is Century Therapeutics, Inc. multi-specific cell therapy for multiple myeloma, adding a plasma-cell cancer target to the pipeline. Multiple myeloma drives about 35,000 new U.S. cases a year, so this program expands the addressable market if the therapy shows durable response and manageable safety in clinic.
- Multi-specific cell therapy candidate
- Targets multiple myeloma
- Adds plasma-cell cancer coverage
Century Therapeutics Builds a Broad iPSC Cell Therapy Pipeline
Century Therapeutics, Inc.'s Product mix is built around six iPSC-derived cell therapy programs: CNTY-101, CNTY-102, CNTY-103, CNTY-104, and CNTY-106. The lead asset is CNTY-101 for relapsed or refractory B-cell lymphoma, while the rest widen coverage into glioblastoma, AML, and multiple myeloma. This gives Century Therapeutics, Inc. a focused, high-unmet-need pipeline across blood and solid tumors.
| Program | Focus |
|---|---|
| CNTY-101 | B-cell lymphoma |
| CNTY-103 | Glioblastoma |
| CNTY-106 | Multiple myeloma |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Century Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Summarizes Century Therapeutics’ 4Ps in a clear, at-a-glance format that speeds alignment and simplifies strategic discussion.
Reference Sources
Provides a concise bibliography linking Century Therapeutics claims to industry reports, clinical data, SEC filings, and trusted benchmarks for fast, defensible due diligence.
Place
Philadelphia, Pennsylvania HQ
Century Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, and was established in 2018. The city serves as the center for its corporate and research work, keeping leadership and R&D close to one site.
This U.S. base supports the company’s cell-therapy development and day-to-day decision-making, which is important for speed in a science-driven business.
Clinical trial site model
Century Therapeutics, Inc. uses a clinical trial site model, so its therapies reach patients through oncology centers and trial sites, not retail shelves. As a clinical-stage biotech, the channel is built around investigator-led studies that test safety and efficacy before any commercial launch. This keeps the go-to-market path tightly tied to trial enrollment and site access.
Allogeneic iPSC manufacturing
Century Therapeutics, Inc. uses an allogeneic iPSC platform, so cell therapy can be made in centralized batches instead of one-by-one for each patient. That makes shipment to treatment sites the operating model, not on-site manufacturing, and it can improve scale and consistency. In 2025-2026, the key advantage is speed and supply control versus autologous therapies, which must be made for each patient.
Hospital administration
Century Therapeutics, Inc. keeps hospital administration tightly tied to the point of care because cell therapies must be infused in hospitals or specialized cancer centers. That model fits the way FDA-cleared cell therapies are handled: certified sites manage cryogenic storage, patient monitoring, and rapid adverse-event response. It also cuts last-mile distribution risk and keeps product flow close to the treating team.
- Administered in hospitals or cancer centers
- Point-of-care delivery reduces handling risk
- Certified sites support safety monitoring
No retail or online channel
Century Therapeutics uses 0 retail stores, 0 pharmacies, and 0 e-commerce channels. Its products are investigational biologics, so access stays inside regulated clinical trial sites now and, if approved later, would shift to specialty oncology distribution. That makes the place strategy fully B2B and clinician-led, not consumer-led.
0 direct consumer channels
Clinical-site access only
Future specialty oncology route
Century Therapeutics: Clinical-Only Access Through Trial Sites and Cancer Centers
Century Therapeutics, Inc. keeps Place fully clinical and B2B: headquarters in Philadelphia, Pennsylvania, and patient access through oncology trial sites and specialized hospitals, not retail. Its centralized allogeneic iPSC model supports shipment to certified treatment centers, which reduces last-mile handling and fits 2025-2026 cell-therapy logistics.
| Place factor | Current setup |
|---|---|
| HQ | Philadelphia, Pennsylvania |
| Channel | Clinical trial sites only |
| Retail channels | 0 |
| Admin sites | Hospitals, cancer centers |
Preview the Actual Deliverable
Century Therapeutics, Inc. Reference Sources
The preview shown here is the actual Century Therapeutics 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises. It’s the full, editable analysis covering Product, Price, Place, and Promotion tailored to Century Therapeutics, ready for immediate use in strategy or reporting.
Promotion
Investor relations
Century Therapeutics' promotion is aimed at investors and analysts, with earnings materials, presentations, and SEC filings doing most of the work. As a pre-commercial biotech, it has no product revenue, so investor relations is key for sharing pipeline updates and cash-runway detail. This is standard for firms still funding research instead of selling approved products.
Press releases
Century Therapeutics uses press releases to announce pipeline, trial, and financing updates, keeping investors aligned with key development milestones. In 2025, public biotech firms still relied on this channel because each trial readout or capital raise can move valuation fast. For Century Therapeutics, these releases are a core promotion tool that supports transparency and market awareness.
Scientific congresses
Scientific congresses let Century Therapeutics, Inc. present preclinical and clinical data to researchers and physicians. Meetings like ASCO, with more than 40,000 attendees, and ASH, with over 30,000, give the company a strong stage to build credibility and peer review. For a biotech with no approved product revenue, that visibility can support trust and partnering interest.
Clinical trial disclosures
Century Therapeutics promotes clinical trial disclosures through public registries and study updates, so investigators and patients can track progress in real time. In 2025, its disclosed pipeline still centered on early-stage allogeneic cell therapy programs, including CTX112 and CTX131, which helped keep trial visibility high. This also supports transparency on development milestones and patient access.
- Public registries raise trial awareness
- Updates improve patient and investigator reach
- Disclosures build trust through transparency
Website and corporate pipeline updates
Century Therapeutics, Inc. uses its website and pipeline pages to show its cell therapy candidates and target indications in one place. That keeps the product story consistent for investors, partners, and analysts. It matters because Century Therapeutics, Inc. does not rely on consumer advertising, so the site is a core channel.
- Clear candidate and indication map
- Single, consistent pipeline story
- Primary channel without consumer ads
In its 2025 reporting, Century Therapeutics, Inc. still had no product sales, so pipeline updates are a key signal of progress.
Century Therapeutics Builds Trust With Pipeline-First Updates
Century Therapeutics, Inc. promotes mainly through investor materials, SEC filings, press releases, and scientific congresses because it had no product sales in 2025. Its CTX112 and CTX131 updates keep analysts, investigators, and partners aligned on pipeline progress and cash use.
| Channel | Role |
|---|---|
| IR, press, congresses | Build trust and visibility |
Price
No approved commercial product
Century Therapeutics, Inc. had no approved commercial therapy as of July 2026, so there is no list price to report. Pricing is not yet applicable because the Company has no marketed product and no sales from an approved therapy. This keeps the price element of the 4P's mix at zero until regulatory approval and launch.
No public list price
Century Therapeutics, Inc. has not disclosed a public list price for CNTY-101 or any other pipeline asset, so the current price is effectively $0 in the market. As a clinical-stage biotech, the company has no retail launch pricing yet, and any price would only come after FDA approval and commercial launch. That means pricing power is still untested, with value tied more to trial data than to a posted price.
Trial supply is sponsor-funded
Century Therapeutics, Inc. trial supply is sponsor-funded, so patients usually pay $0 for the investigational therapy. In clinical development, access comes through site enrollment and protocol rules, not a market sale. That keeps pricing out of the patient channel until any approved product reaches a paid market.
Hospital and payer negotiation
If Century Therapeutics, Inc. wins approval, hospital and payer negotiation will set the net price. In U.S. cell therapy, specialty medical benefit coverage is common, and public list prices for CAR-T drugs have ranged from about $373,000 to $487,000 per treatment.
The final price will hinge on prior auth, outcomes data, and hospital margin pressure. A strong value case can lift coverage; weak evidence can force discounts or risk-based deals.
- Negotiated with hospitals and payers
- Specialty medical channel reimbursement
- Coverage drives net realized price
Specialty oncology pricing model
Century Therapeutics' cancer cell-therapy pipeline sits in premium specialty biologics, where U.S. CAR-T list prices often range from about $373,000 to $475,000 per treatment. That pricing fits the high unmet need and complex manufacturing, including patient-specific cell processing and cold-chain delivery. In this class, price is tied more to clinical value and production difficulty than to volume.
- Premium, hospital-based oncology use
- Complex manufacturing lifts price
- High unmet need supports premium pricing
Century Therapeutics Price: $0 Now, CAR-T Pricing Could Be $373K-$487K
Century Therapeutics, Inc. had no approved product as of July 2026, so its Price stays at $0 for now. In trials, patients usually pay $0 because sponsor-funded supply is used. If approved, pricing will be set by hospital and payer talks, with CAR-T list prices often around $373,000 to $487,000 per treatment.
| Metric | Price |
|---|---|
| Current list price | $0 |
| Trial patient cost | $0 |
| Likely future class range | $373,000-$487,000 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.